Intratect 100 g/L, solution for infusion Irland - engelska - HPRA (Health Products Regulatory Authority)

intratect 100 g/l, solution for infusion

biotest pharma gmbh - human plasma protein - solution for infusion - 100 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

Intratect 50 g/L, solution for infusion Irland - engelska - HPRA (Health Products Regulatory Authority)

intratect 50 g/l, solution for infusion

biotest pharma gmbh - human plasma protein >96% immunoglobulins - solution for infusion - 50 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

Gammaplex 10%100 mg/ml solution for infusion Irland - engelska - HPRA (Health Products Regulatory Authority)

gammaplex 10%100 mg/ml solution for infusion

bio products laboratory limited - human normal immunoglobulin - solution for infusion - 100 milligram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

Gammaplex 10%100 mg/ml solution for infusion Irland - engelska - HPRA (Health Products Regulatory Authority)

gammaplex 10%100 mg/ml solution for infusion

bpl bioproducts laboratory gmbh - human normal immunoglobulin - solution for infusion - 100 milligram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

SANDOGLOBULINE I.V 1 G Israel - engelska - Ministry of Health

sandoglobuline i.v 1 g

mediline ltd. - immunoglobulin normal human 1 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

SANDOGLOBULINE I.V 6 G Israel - engelska - Ministry of Health

sandoglobuline i.v 6 g

mediline ltd. - immunoglobulin normal human 6 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

SANDOGLOBULINE I.V 3 G Israel - engelska - Ministry of Health

sandoglobuline i.v 3 g

mediline ltd. - immunoglobulin normal human 3 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

GAMMAGARD S/D IMMUNE GLOBULIN I.V. 2.5 G Israel - engelska - Ministry of Health

gammagard s/d immune globulin i.v. 2.5 g

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

GAMMAGARD S/D IMMUNE GLOBULIN I.V. 5 G Israel - engelska - Ministry of Health

gammagard s/d immune globulin i.v. 5 g

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

GAMMAGARD S/D IMMUNE GLOBULIN I.V. 10 G Israel - engelska - Ministry of Health

gammagard s/d immune globulin i.v. 10 g

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation